CJC‑1295 (No DAC) & Ipamorelin: Synergistic Growth Hormone Release in Human and Animal Models

Study: Factor I Secretion by CJC 1295, a Long‑Acting GHRH Analog, in Healthy Adults

Journal of Clinical Endocrinology & Metabolism, 2005 – Phase I human trial of CJC‑1295 (with and without DAC), GH and IGF‑1 dynamics under dosing protocols Physio Logic NYC

Although this study focused solely on CJC‑1295 (with DAC), it clearly establishes the pharmacokinetic and hormonal profile and lays the groundwork for its synergistic use with Ipamorelin in subsequent research applications.

Research Overview

This double-blind, placebo-controlled trial assessed healthy volunteers (ages 21–61) who received subcutaneous injections of CJC‑1295 (without DAC variant included). The goal was to evaluate the dose-dependent stimulation of both growth hormone (GH) and insulin-like growth factor‑1 (IGF‑1).

Patients received single ascending doses as well as multiple weekly or biweekly doses. GH responses, IGF‑1 kinetics, and safety/tolerability markers were rigorously tracked across study durations of up to 49 days

Key Outcomes

• GH concentration increased 2‑ to 10‑fold, lasting up to 6 days post-injection.

• IGF‑1 levels rose 1.5‑ to 3‑fold, remaining elevated for up to 9–11 days, with multiple-dose regimens trending to sustained elevation for up to 28 days.

• The estimated half‑life of CJC‑1295 averaged 5.8–8.1 days, regardless of dosage frequency.

• No serious adverse events reported; peptide was generally well tolerated, particularly at doses within the 30–60 µg/kg range

Mechanistic Insight into Synergy with Ipamorelin

Complementary Pathways

• CJC‑1295 (No DAC) acts as a growth hormone–releasing hormone (GHRH) analog, stimulating the pituitary to produce GH for an extended duration.

• Ipamorelin is a ghrelin receptor agonist (GHRP) that induces pulsatile GH release via GHS‑R1a, with minimal effects on cortisol, prolactin, insulin, etc.

Synergistic Effect

When combined, these peptides act on distinct yet complementary pathways:

1. CJC‑1295 increases baseline GH secretion and duration

2. Ipamorelin introduces sharp GH pulses, amplifying secretion intensity

3. Together, they yield greater hormone release than either alone, enhancing potential anabolic and metabolic signals without elevated off-target hormones.

Human user reports and preclinical commentary suggest this pairing may improve body composition (fat oxidation, lean mass retention), recovery, and metabolic regulation in research settings Reddit.

⚠️ Caution & Adverse Events Observed

Studies and anecdotal reports indicate:

• Mild side effects: injection site reactions, water retention, joint stiffness, headaches, tingling, and occasional numbness

• Sleep disturbances (e.g. vivid dreams, increased sleepiness) reported in user forums with combined dosing protocols

• Rare reports of cardiac conduction anomalies and elevated insulin resistance with long-term use

Research Applications & Study Relevance

GH/IGF‑1 Axis Modulation

• CJC‑1295 enhances GH/IGF‑1 baseline signaling.

• Ipamorelin adds frequency and intensity via pulsatile release, potentially optimizing downstream responses.

This makes the combo ideal for:

• Studies on muscle mass regulation & fat tissue modeling

• Investigations into growth hormone receptor sensitivity

• Models analyzing metabolic flexibility and recovery in rodents or tissue cultures (e.g., skeletal muscle cell lines or adipocyte differentiation assays).

Body Composition & Fat Regression Models

• Preclinical studies show that GH analogs (e.g., CJC‑1295) and GHRPs promote fat oxidation, reduced visceral adipose tissue, and improved lean mass retention, even in calorically restricted environments

• Relevant research protocols could include diet-induced obesity models, lipodystrophy models, or muscle recovery post-injury.

⚠️ Research Use Disclaimer

This summary is strictly for laboratory research purposes only. These peptides are not FDA- or Health Canada–approved for any human use. Findings should be applied only within in vitro, ex vivo, or animal model systems under controlled environments.

References

1. Teichman SL et al. CJC 1295, a long-acting growth hormone releasing hormone analog, increases IGF-1 in humans. J Clin Endocrinol Metab. 2006 Apr;91(4):799–805. https://doi.org/10.1210/jc.2005-1536

2. Physio Logic NYC. Peptide Therapy: CJC 1295 & Ipamorelin (Brooklyn, NYC).
   https://physiologicnyc.com/peptide-therapy-brooklyn-nyc/peptide-therapy-cjc-1295-ipamorelin-subcutaneous

3. Polaris Peptides. CJC 1295 and Ipamorelin: Synergy in Growth Hormone Research.
   https://polarispeptides.com/cjc-1295-and-ipamorelin

4. Stardust Peptides. CJC 1295 & Ipamorelin Side Effects – Research Summary.
   https://stardustpeptides.com/blogs/news/cjc-1295-ipamorelin-side-effects-research

5. Semprefit Research. The Potential Power of CJC 1295 and Ipamorelin.
   https://semprefitresearch.com/peptides/the-potential-power-of-cjc-1295-and-ipamorelin

6. Jay Campbell. CJC 1295/Ipamorelin Stack for Recovery and Anti-Aging.
   https://jaycampbell.com/peptides/cjc-1295-ipamorelin-stack

7. Peptide Sciences. CJC 1295 vs. Ipamorelin – What’s the Difference?
   https://www.peptidesciences.com/peptide-research/ipamorelin-vs-cjc-1295

8. Reddit – r/Peptides, r/SARMs, r/BodyHackGuide – Community commentary and user experience reports.
   https://www.reddit.com/r/Peptides